Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $630.2 million.

  • Ascendis Pharma A's Cash & Equivalents fell 825.74% to $630.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.2 million, marking a year-over-year decrease of 825.74%. This contributed to the annual value of $605.6 million for FY2024, which is 4352.94% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash & Equivalents of $630.2 million as of Q3 2025, which was down 825.74% from $559.2 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Cash & Equivalents registered a high of $848.1 million during Q1 2022, and its lowest value of $278.6 million during Q2 2024.
  • In the last 5 years, Ascendis Pharma A's Cash & Equivalents had a median value of $544.8 million in 2025 and averaged $554.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 4016.82% in 2023, then surged by 10074.2% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash & Equivalents (Quarter) stood at $510.5 million in 2021, then fell by 11.12% to $453.8 million in 2022, then dropped by 7.01% to $421.9 million in 2023, then skyrocketed by 41.71% to $597.9 million in 2024, then rose by 5.4% to $630.2 million in 2025.
  • Its Cash & Equivalents was $630.2 million in Q3 2025, compared to $559.2 million in Q2 2025 and $544.8 million in Q1 2025.